What's in Prof JMA Lange's pipeline?

Prof JMA Lange has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Prof JMA Lange's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/prof-jma-lange.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Prof JMA Lange — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prof JMA Lange pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ART only arm	ART only arm	marketed			Infectious Disease / Virology
Experimental: Empiric TB treatment	Experimental: Empiric TB treatment	marketed	Anti-tuberculous agent combination		Infectious Disease

Therapeutic area mix

Infectious Disease · 1
Infectious Disease / Virology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Prof JMA Lange:

Cite this brief

Drug Landscape (2026). Prof JMA Lange — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/prof-jma-lange. Accessed 2026-06-10.